文献速递白血病造血干细胞移植与细胞治疗

贝林妥欧单抗在先天性免疫缺陷相关T细胞免疫受损的淋巴细胞白血病中仍有活性

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency.
PubMed 文献 · Blood Adv · 2021-01-01

本文报告2例合并先天性T细胞免疫缺陷的B前体急性淋巴细胞白血病(BCP-ALL)患者,接受贝林妥欧单抗后均获得微小残留病阴性(MRD-)缓解。提示无论先天性或获得性T淋巴细胞减少,均不影响贝林妥欧单抗疗效。

要点

  • 贝林妥欧单抗可在先天性T细胞免疫缺陷的BCP-ALL中诱导MRD-缓解。
  • T淋巴细胞减少(先天性或获得性)不损害贝林妥欧单抗疗效。
  • 贝林妥欧单抗可作为化疗减量桥接移植的手段。

核心结论

  • T淋巴细胞减少无论先天性或获得性,均不损害贝林妥欧单抗的疗效。

研究设计与样本

  • 病例报告,共2例合并先天性T细胞免疫缺陷的BCP-ALL患者。

主要发现

  • 第1例为6岁女孩,患Schimke免疫-骨发育不良(SIOD)及联合免疫缺陷(CID),高超二倍体BCP-ALL经贝林妥欧单抗获得MRD-缓解,末次随访时缓解自诊断起已持续14个月。
  • 第2例为9岁男孩,患Omenn综合征及CID,4月龄接受母亲不合配骨髓移植,移植后9年诊断t(3;11)+(KMT2A-LARS2)BCP-ALL;持续MRD经4药诱导后予贝林妥欧单抗作为化疗减量桥接移植,获得MRD-缓解。

临床怎么用

  • 对合并先天性T细胞免疫缺陷的BCP-ALL患者,贝林妥欧单抗仍可考虑用于清除MRD。
  • 贝林妥欧单抗可作为化疗减量方案桥接造血干细胞移植。

局限性

  • 仅为2例病例报告,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blinatumomab, a single-chain, bispecific, T-cell-engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency. We report 2 patients with BCP-ALL and congenital T-cell immunodeficiency, who obtained an excellent response to blinatumomab. The first, a 6-year-old girl with Schimke immuno-osseous dysplasia (SIOD) and combined immunodeficiency disorder (CID) obtained a minimum residual disease-negative (MRD-) remission of high hyperdiploid BCP-ALL with blinatumomab. At last follow-up, the remission had been sustained for 14 months from diagnosis. The second was a 9-year-old boy with Omenn syndrome and CID who received a mismatched bone marrow transplant from his mother at the age of 4 months and was diagnosed with t(3;11)+ (KMT2A-LARS2) BCP-ALL 9 years after his transplant. He received a 4-drug induction followed by blinatumomab for persistent MRD as a chemotherapy-sparing bridge to transplant and achieved an MRD- remission. T-lymphopenia, whether congenital or acquired, does not compromise the efficacy of blinatumomab.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ramdeny S, Chaudhary A, Worth A, et al. Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency. Blood Adv. 2021. PMID: 33881461. doi:10.1182/bloodadvances.2021004284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。